1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTherapeutic Giving: Pulmonary Arterial Hypertension Grant is sponsored by Johnson & Johnson Innovative Medicine. Supports nonprofit organizations enhancing patient access to treatment and services for pulmonary arterial hypertension, addressing health disparities.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Sorry, I don't understand. Please try again Pulmonary Hypertension focuses on the discovery, development and commercialization of innovative treatments to serve critical, unmet medical needs. We strive on delivering ground-breaking medicines that improve patients’ lives.
We offer funding and support because we believe organizations are an important support network and source for raising awareness and providing education. What are Pulmonary Hypertension US Educational Objectives? Increase awareness of Pulmonary Arterial Hypertension (PAH) and associated diseases.
Increase awareness of the need for early recognition, diagnosis, and treatment of PAH. Expand knowledge basis for the appropriate use of currently available PAH therapies. Explore emerging science as it relates to improved diagnosis and treatment of PAH.
What therapeutic areas will be considered by Pulmonary Hypertension? Pulmonary Hypertension supports legitimate, independent, bona fide educational programs related to PAH and other therapeutic areas and disease states consistent with the medical and research objectives developed by Pulmonary Hypertension’s Medical Affairs Department. 1.
Pulmonary Arterial Hypertension Continuing Medical Education (Pulmonologists, Cardiologists, RPh, NPs/PAs, PCPs, Rheums) Meth associated pulmonary arterial hypertension Pulmonary arterial hypertension and connective tissue disease Pulmonary arterial hypertension – imaging through Echocardiography Risk/Benefit with treatment Impact of disease progression Consider requests from top academic institutions Preferred Delivery Methods/Geographic Scope: Live and virtual activities, Dinner Programs, Grand Rounds, Local and regional meetings, On-site (in a clinic or community hospital) with healthcare teams.
Certificate Of Separation: Please Click here to view Certificate Of separation. For general questions please email Rocket Romer, Pulmonary Arterial Hypertension Grants Manager at: rromer2@its. jnj.
com . Click here to submit an Independent Medical Education Grant
According to the current listing, eligibility includes: Nonprofit organizations with 501(c)(3) status in the United States. Confirm the full requirements in the official notice before applying.
Therapeutic Giving: Pulmonary Arterial Hypertension Grant is funded by Johnson & Johnson Innovative Medicine. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
EPA's Innovative Water Infrastructure Workforce Development competition closes October 5, 2026. The agency says up to 15 awards across four project areas, but Project Area 1 alone carries a $7.8 million ceiling against a $10.8 million pot. That tension is the single most important strategic fact in the NOFO — here is how to read it, which lane is least competed, and what a three-week runway means for your submission.
Read articleThe FY2026 Innovative Water Infrastructure Workforce Development Grant (EPA-OW-OWM-26-03) closes October 5, 2026 with $10.8 million, up to 15 cooperative agreements, and a Project Area 1 ceiling of $7.8 million. One maximum award would consume 72 percent of the pool. Here is how the four project areas actually partition the money, why the grants.gov award floor field is wrong, and why September 14 is the date that matters more than October 5.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read article